These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 26943643)
1. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643 [TBL] [Abstract][Full Text] [Related]
2. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536 [TBL] [Abstract][Full Text] [Related]
3. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893 [TBL] [Abstract][Full Text] [Related]
5. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657 [TBL] [Abstract][Full Text] [Related]
6. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837 [TBL] [Abstract][Full Text] [Related]
7. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder. Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614 [TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554 [TBL] [Abstract][Full Text] [Related]
9. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. Tilki D; Shariat SF; Lotan Y; Rink M; Karakiewicz PI; Schoenberg MP; Lerner SP; Sonpavde G; Sagalowsky AI; Gupta A BJU Int; 2013 Jun; 111(8):1215-21. PubMed ID: 23181623 [TBL] [Abstract][Full Text] [Related]
10. A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. Di Trapani E; Sanchez-Salas R; Gandaglia G; Rocchini L; Moschini M; Lizee D; Carneiro A; Sivaraman A; Barret E; Rozet F; Galiano M; Bennamoun M; Colombo R; Suardi N; Briganti A; Montorsi F; Cathelineau X World J Urol; 2016 Feb; 34(2):207-13. PubMed ID: 26198750 [TBL] [Abstract][Full Text] [Related]
11. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. Engel O; Soave A; Peine S; Kluth LA; Schmid M; Shariat SF; Dahlem R; Fisch M; Rink M World J Urol; 2015 Nov; 33(11):1769-76. PubMed ID: 25782867 [TBL] [Abstract][Full Text] [Related]
12. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452 [TBL] [Abstract][Full Text] [Related]
13. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839 [TBL] [Abstract][Full Text] [Related]
14. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M; Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925 [TBL] [Abstract][Full Text] [Related]
15. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082 [TBL] [Abstract][Full Text] [Related]
16. Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Rouprêt M; Drouin SJ; Larré S; Neuzillet Y; Botto H; Hitier M; Rigaud J; Crew J; Xylinas E; Salomon L; Cornu JN; Iborra F; Champetier D; Rozet F; Flamand V; Bastide C; Cormier L; Durand X; Lunardi P; Rischmann P; Nouhaud FX; Ferlicot S; Patard JJ; Floch AP; Irani J; Peyronnet B; Bensalah K; Poissonnier L; Grès P; Droupy S; Casenave J; Wallerand H; Soulié M; Pfister C; Ann Surg Oncol; 2011 Dec; 18(13):3833-8. PubMed ID: 21647762 [TBL] [Abstract][Full Text] [Related]
17. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469 [TBL] [Abstract][Full Text] [Related]
18. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657 [TBL] [Abstract][Full Text] [Related]
19. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Kassouf W; Spiess PE; Brown GA; Munsell MF; Grossman HB; Siefker-Radtke A; Dinney CP; Kamat AM Eur Urol; 2007 Sep; 52(3):769-74. PubMed ID: 17434254 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]